المساهمون: Ding-Wei Ye, Clinical Professor

المصدر: A Prospective, Open, Single-center Clinical Study of Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06187506Test

المصدر: DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With Locally Advanced or Metastatic HER2 IHC2+/3+ Esophageal Squamous Cell Carcinoma

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06055153Test

المصدر: Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations Independent of HER2 Expression With Progression After Previous Treatment

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05904730Test

Other URLs: https://pubmed.ncbi.nlm.nih.gov/24755544Test/
https://www.pennmedicine.org/news/news-releases/2022/november/why-cancers-caused-by-brca-mutations-recurTest
https://hccpjournal.biomedcentral.com/articles/10.1186/s13053-021-00193-yTest

المصدر: PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05868226Test

المصدر: Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05511844Test

المؤلفون: AstraZeneca

المصدر: BrUOG 413: A Phase II Study of Adjuvant Trastuzumab Deruxtecan (Enhertu) + Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2-Positive Cancers of the Esophagus and Gastroesophageal Junction

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05480384Test

المصدر: A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05363605Test

Other URLs: http://fusionpharma.comTest

المؤلفون: Odense University Hospital, Aalborg University Hospital, Aarhus University Hospital

المساهمون: Morten Mau-Sørensen, MD PhD

المصدر: HERES Trial: Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05170256Test

المؤلفون: Center for Cell and Gene Therapy, Baylor College of Medicine, The Faris Foundation USA, Stand Up To Cancer, Triumph Over Kid Cancer Foundation, St. Baldrick's Foundation, National Cancer Institute (NCI)

المساهمون: Meenakshi Hegde, M.D., Associate Professor

المصدر: Phase I Study of HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04995003Test

Other URLs: https://rarediseases.info.nih.govTest/

المؤلفون: National Institutes of Health (NIH)

المصدر: Imaging of HER2-expressing Cancer With Site-Specifically Labeled 89Zr-ss-Pertuzumab

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04692831Test

Other URLs: http://www.mskcc.orgTest